Login to Your Account



3Sbio gaining bigger stake in Chinese MAb company CP Guojian

By Cornelia Zou
Staff Writer

Monday, November 23, 2015

HONG KONG – 3Sbio Inc., a biopharmaceutical company that has returned to a stock market in China after delisting abroad, has taken a further step in its newfound home market by acquiring shares of a leading biosimilar MAb maker to build the largest biological drug platform in China.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription